ORIGINAL ARTICLE

JOP. J Pancreas (Online) 2006; 7(1):34-40.

Combined Chemoradiotherapy for Isolated Local Recurrence after Primary Resection of Pancreatic Cancer

Ralf Wilkowski1, Martin Thoma1, Christiane Bruns2, Eckhard Dühmke1, Volker Heinemann3

1Clinic for Radiation Oncology, 2Surgical Clinic, and 3Medical Clinic III, LMU University Hospital Grosshadern. Munich, Germany

ABSTRACT

Context Primary resectability is expected in up to 20% of pancreatic cancer patients. While most patients relapse with distant metastases, approximately 30% of patients show isolated local recurrence without evidence of distant metastases.

Objective The present analysis investigates the efficacy of chemoradiotherapy in this particular patient group.

Design Retrospective study.

Patients Eighteen consecutive pancreatic cancer patients presenting with isolated locoregional recurrence after surgical resection. The median interval between primary surgery and diagnosis of local recurrence was 10.4 months (range: 2.0-19.3 months).

Interventions Patients received 3-D conformal radiation with 45 Gy in 25 fractions of 1.8 Gy/day. Simultaneous chemotherapy was employed either with continuous 5-FU infusion, partly in combination with gemcitabine, or with gemcitabine and cisplatin. Sequential chemotherapy with gemcitabine and cisplatin was given to some patients before and after the chemoradiotherapy.

Results In 17 of the 18 patients included, radiotherapy was employed at the intended dose. While WHO grade 3-4 gastrointestinal toxicity was not reported, hematotoxicity was more pronounced. Grades 3 and 4 leukocytopenia occurred in 4 patients (22.2%) and 1 (5.6%) patient, respectively, and grades 3 and 4 thrombocytopenia occurred in 4 patients (22.2%) and 1 patient(5.6%), respectively. Six (37.5%) complete remissions, 6 (37.5%) partial remissions, and 4 (25.0%) stable diseases were noted in 16 evaluable patients. Median progression-free survival calculated from the start of the chemoradiotherapy was 14.7 months (range: 8.4-21.0 months) . Seven (28.9%) patients had another local relapse, while 11 (61.1%) patients developed distant metastases. Median overall survival from the start of the chemoradiotherapy was 17.5 months (95% CI: 15.6-19.4 months) and median survival from the initial diagnosis was 27.2 months (95% CI: 23.9-30.6 months).

Conclusion The data provide a first indication that chemoradiotherapy is feasible and may be an effective treatment option in those patients who present with local metastasis after primary surgery for pancreatic cancer.

Full text  HTML format  PDF format
Look up who cited this article

References

  1. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6:19-28. [More details]

  2. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66:56-61. [More details]

  3. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230:776-82. [More details]

  4. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21:195-200. [More details]

  5. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976; 37:1519-24. [More details]

  6. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225:621-33. [More details]

  7. Menke-Pluymers MB, Klinkenbijl JH, Tjioe M, Jeekel J. Treatment of locoregional recurrence after intentional curative resection of pancreatic cancer. Hepatogastroenterology 1992; 39:429-32. [More details]

  8. Westerdahl J, Andren-Sandberg A, Ihse I: Recurrence of exocrine pancreatic cancer - local or hepatic? Hepatogastroenterology 1993; 40:384-7. [More details]

  9. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [More details]

  10. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7:347-53. [More details]

  11. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94:902-10. [More details]

  12. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002; 29(6 Suppl 20):9-16. [More details]

  13. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002; 95:912-22. [More details]

  14. Mose S, Class R, Weber HW, Oszvald A, Rahn A, Brady LW, Bottcher HD. Combined radiotherapy and gemcitabine. Evaluation of clinical data based on experimental knowledge. Strahlenther Onkol 2002; 178:59-70. [More details]

  15. Wilkowski, R., Heinemann, V., Rau, H. G. Radiochemotherapy Including Gemcitabine and 5-Fluorouracil for Treatment of Locally Advanced Pancreatic Cancer. Proc Am Soc Clin Oncol 2000; 19:A1078. [More details]

  16. Wilkowski R, Thoma M, Heinemann V, Rau HG, Wagner A, Stoffregen C, Duhmke E. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective. Strahlenther Onkol 2003; 179:78-86. [More details]

  17. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80:751-5. [More details]

  18. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987; 59:2006-10. [More details]

  19. Arbuck SG, Ivy SP, Setser A. The Revised Common Toxicity Criteria: Version 2.0. CTEP Cancer Therapy Evaluation Program Website 1. [More details]

  20. Sunamura M, Egawa S, Shibuya K, Shimamura H, Takeda K, Kobari M, Matsuno S. Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy. Nippon Geka Gakkai Zasshi 1999; 100:200-5. [More details]

  21. Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004; 28:1011-8. [More details]

  22. Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, Carbone P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55. [More details]

  23. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 6th ed. New Jersey: John Wiley & Sons, 2002. [More details]

Keywords Combined Modality Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms /surgery

Correspondence Martin Thoma: martin.thoma@med.uni-muenchen.de

JOP Home page